Results 291 to 300 of about 145,800 (401)

Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims There is a potential risk of systemic side‐effects with the use of potent corticosteroids, such as clobetasol propionate (CP). This concern is of particular interest in paediatric patients. The aim of this study was to develop and verify a physiologically based pharmacokinetic (PBPK) model to describe the local and systemic exposure to CP
Janna K. Duong, Sven van Dijkman, Gary Ong, Alexandra Marta, Adriana Ceci, Ernesto Bonifazi, Oscar Della Pasqua   +6 more
wiley   +1 more source

The Development of a Multilayer Transdermal Patch Platform Based on Electrospun Nanofibers for the Delivery of Caffeine. [PDF]

Pharmaceutics
Teno J, Evtoski Z, Prieto C, Lagaron JM.
europepmc   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Commentary on “Transdermal DMPS” [PDF]

Journal of Medical Toxicology, 2012
openaire   +2 more sources

Repurposing losartan potassium against rheumatoid arthritis via transdermally-delivered leciplexes: Accentuated efficacy through modulation of angiotensin II/AT1R/AT2R axis. [PDF]

Int J Pharm X
Hussein AA, Aldosari BN, Zaki RM, Afzal O, Ali AA, Aboud HM, Ahmed YM, Naguib DM.   +7 more
europepmc   +1 more source

Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy

, 1998
Douglas E. Wilson, Kays H. Kaidbey, Steven C. Boike, Diane K. Jorkasky   +3 more
openalex   +1 more source

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies

British Journal of Clinical Pharmacology, EarlyView.
Aims The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton‐pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are ...
Daan W. Huntjens, Olivier J. M. Béquignon, Stefanie D. Krens, Mark Löwenberg, Martine E. D. Chamuleau, Remco J. Molenaar, Anita M. G. Kramers, Marianne A. Kuijvenhoven, Imke H. Bartelink   +8 more
wiley   +1 more source

Construction and applications of exosome-microneedle integrated systems. [PDF]

Int J Pharm X
Zheng L, Sun J, Wang L, Ding Z, Tang Y, Dai M, Tang H.   +6 more
europepmc   +1 more source

Medication persistence trajectories among individuals prescribed lipid‐lowering therapy in primary care settings: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to identify distinct trajectories of lipid‐modifying medication (LMM) persistence over time and to explore characteristics associated with each pattern. Methods Using primary care data from IQVIA, we conducted a retrospective cohort study of adults prescribed LMMs between January 2015 and December 2017, with 5 years of follow‐up ...
Zhomart Orman, Jia Wei Koh, Caroline Trin, Zanfina Ademi, Ella Zomer, Danielle Berkovic, Jenni Ilomaki, J. Simon Bell, Danny Liew, Christopher M. Reid, Sean Lybrand, Brittany Schoeninger, Stella Talic   +12 more
wiley   +1 more source

Terpenes and Essential Oils in Pharmaceutics: Applications as Therapeutic Agents and Penetration Enhancers with Advanced Delivery Systems for Improved Stability and Bioavailability. [PDF]

Pharmaceutics
Kaspute G, Ivaskiene T, Ramanavicius A, Ramanavicius S, Prentice U.   +4 more
europepmc   +1 more source